PacBio Slashes 2026 Revenue Outlook to $155M–$165M, Delays Breakeven to 2028
PACB is trading near its 52-week low of $1.09 (8.7% above the low).
Summary
PacBio cut its 2026 revenue guidance to $155M–$165M, well below prior expectations, and pushed cash-flow breakeven out to 2028. The company also provided new margin and expense targets: non-GAAP gross margin of 35%–37% and operating expenses of $215M–$220M, with year-end cash projected at $175M–$185M. This follows last week's Q2 miss and CEO transition, adding concrete numbers to the deteriorating outlook. The Vega SPRQ-Nx launch by month-end offers a potential catalyst with higher yield and lower pricing, but the near-term financial picture is grim.
At the time of this announcement, PACB was trading at $1.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $368.3M. The 52-week trading range was $1.09 to $2.73. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.